Hepatocellular carcinoma · 4 regimens
Cost vs Efficacy
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
Atezolizumab and Bevacizumab Variant #01 | — | R 59 878 | 21d | — | ~19.2 mo | — | — | 1 |
Observation Partial | — | — | — | — | — | — | — | 1 |
TACE monotherapy Variant #01 Partial | — | — | — | — | — | — | — | 1 |
Placebo Partial | — | — | — | ~2.3 mo | ~7.6 mo | — | — | 16 |
4 of 4 regimens shown